Eight landmark achievements in the field of life sciences

He won the Outstanding Scientific and Technological Achievement Award of the Chinese Academy of Sciences in 2003, and was selected as one of the top Ten scientific and technological discoveries in the world in 2007 by Time Magazine and the top ten scientific breakthroughs in 2014 by Science Magazine.

Through the discovery and study of the earliest fossils of modern humans in East Asia 80,000 to 120,000 years ago, the Institute of Palaeontology denied part of the "African origin theory" of modern humans, and proposed a new hypothesis of the emergence and diffusion of modern humans in East Asia, providing important fossil evidence for the study of human evolution in East Asia, and pushing the study of ancient human evolution in China to the international frontier level. The related achievements were selected as Nature's top ten scientific Events in 2014.

Stem cell and regenerative medicine research

In 2009, the cooperative method of animals for the first time used induced pluripotent stem cells (iPS cells), through tetraploid blastocyst injection to survive and have the ability to reproduce mice, the first time in the world to prove the totipotency of iPS cells, for further research iPS technology in the field of stem cells, developmental biology and regenerative medicine to provide a technical platform. He won the Outstanding Scientific and Technological Achievement Award of the Chinese Academy of Sciences in 2013.

Since then, the institute has also taken the lead in establishing mammalian solitary male and parthenogenetic haploid embryonic stem cell lines, and has formed an internationally advantageous technical system for functional gene screening and research. It is found that parthenogenetic haploid stem cells can replace sperm after modification of genomic imprinting, and a new method of "homosexual reproduction" has been established.

In 2012, the Guangzhou Institute of Biology used urine epithelial cells to induce the generation of neural stem cells, providing a new way for the treatment of neurological diseases.

In 2016, the Center of Excellence in Molecular and Cellular Science successfully used transdifferentiation technology to construct liver cells, developed a new type of bioartificial liver, treated and saved more than 10 cases of liver failure patients, and achieved industrial transformation.

Since 2015, the Institute of Genetic Development has used nerve regeneration collagen scaffolds combined with cell transplantation to treat spinal cord injury and achieved good results. From 2013 to 2018, the use of stem cells combined with collagen scaffolds to treat endometrial injury and premature ovarian failure was successful, and it is expected to become an effective therapy for female reproductive system diseases.

New drug development

Shanghai Pharmaceutical Institute innovatively developed salvia polyphenolate and its powder injection, which obtained the new drug certificate and production approval in May 2005, and was rated as the most competitive pharmaceutical variety in the market by the Chinese pharmaceutical industry.

Since it was put into operation in 2006, the cumulative sales revenue has exceeded 20 billion yuan, benefiting more than 15 million patients, and has a demonstration role in the modernization of Chinese traditional medicine. He won the Outstanding Scientific and Technological Achievement Award of the Chinese Academy of Sciences in 2013.

In 2009, Shanghai Pharmaceutical Institute spent more than 10 years to independently develop China's first national class fluoroquinolone antibacterial drug with independent intellectual property rights, antofloxacin hydrochloride, which significantly improved the antibacterial activity and metabolic properties, breaking the situation of China's long-term reliance on generic drugs.

After more than 20 years of efforts, on July 17, 2018, the mannooligosaccharic acid (GV-971) jointly developed by Shanghai Pharmaceutical Institute completed the phase III clinical trial, and the cure effect was obvious, marking a major breakthrough in China's new drug for the treatment of Alzheimer's disease with independent intellectual property rights.

The novel mode of action and unique multi-target action characteristics of GV-971 have subverted the traditional understanding of the pathogenesis of Alzheimer's disease by the world medical community on the drug antitofloxacin hydrochloride Diaoxuenkang capsule mannooligosaccharide (GV-971) capsule tumor immune targeting small molecule inhibitor, and opened up a new path for the development of Alzheimer's disease drugs.

In 2014, Shanghai Institute of Organics developed tumor immune targeting small molecule inhibitor (IDO) - indoleamine 2, 3-dioxygenase, which can be used to treat prostate cancer, pancreatic cancer, breast cancer, stomach cancer and other tumor diseases. In September 2017, the license was transferred to domestic biopharmaceutical enterprises for $457 million.

Studies on distant hybridization and molecular breeding

After more than 50 years of unremitting efforts, the Institute of Genetics and Development has cultivated a new wheat variety of "Small Yan" series through systematic remote hybridization research, which has opened up a new way for wheat chromosome engineering breeding.